A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

This study is testing the combination of mosunetuzumab (a bispecific antibody that helps your immune system attack cancer cells) and zanubrutinib (a targeted pill that blocks cancer cell growth signals) in patients with marginal zone lymphoma — a slow-growing blood cancer — that has come back or stopped responding to prior treatment. **You may be eligible if...** - You are 18 or older and have been diagnosed with marginal zone lymphoma (any subtype) - Your lymphoma has come back or is no longer responding to your most recent treatment, including a prior CD20-targeted therapy (like rituximab) - You have stage II, III, or IV disease - You are in reasonable health (ECOG ≤2) - Your lymphoma is causing symptoms, affecting organ function, or growing significantly **You may NOT be eligible if...** - You have had a prior stem cell transplant - Your lymphoma has transformed into a more aggressive type - You have active, uncontrolled infection including hepatitis B/C or HIV - You are pregnant or breastfeeding - You have significant heart problems Talk to your doctor to see if this trial is right for you.